[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356304-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356304-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-role-of-cdca3-in-lung-adenocarcinoma-with-immune-infiltration","Prognostic role of CDCA3 in lung adenocarcinoma with immune infiltration","","Lung cancer causes high cancer-related mortality and often resists conventional platinum chemotherapy, making new biomarkers and immunotherapy targets urgently needed. This study evaluates CDCA3 as a prognostic marker in lung adenocarcinoma (LUAD) and links its expression to immune infiltration and immune checkpoint activity. Using TCGA data and Kaplan–Meier survival analysis, CDCA3 is upregulated in tumors and associates with worse overall survival and clinical features. Immune profiling connects CDCA3 with activated memory T cells, macrophage polarization, T-cell exhaustion, immune scores, and checkpoint gene expression, while drug-sensitivity results suggest CDCA3 may influence chemotherapy response. In vitro CDCA3 knockdown in A549 cells reduces expression and increases apoptosis, supporting a role in LUAD proliferation and survival.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-role-of-cdca3-in-lung-adenocarcinoma-with-immune-infiltration/356304/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-role-of-cdca3-in-lung-adenocarcinoma-with-immune-infiltration/356304.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does CDCA3 expression indicate for patients with lung adenocarcinoma (LUAD)?","Question",{"text":63,"@type":64},"CDCA3 is upregulated in LUAD tumor tissues, and higher expression is linked to poorer overall survival.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is CDCA3 related to immune infiltration in LUAD?",{"text":68,"@type":64},"Immune infiltration analysis shows associations between CDCA3 levels and immune components including CD4-activated memory T cells and macrophages, with single-cell data indicating altered proportions of CD8⁺ exhausted and cytotoxic T cells and M1/M2 macrophages.",{"name":70,"@type":61,"acceptedAnswer":71},"What experimental evidence supports CDCA3’s functional role in LUAD cells?",{"text":72,"@type":64},"In A549 cells, CDCA3 knockdown reduces CDCA3 mRNA and protein levels, and flow cytometry indicates increased apoptosis, consistent with CDCA3 promoting LUAD cell proliferation and survival.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356304,1790445852,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPrognostic role of CDCA3 in lung adenocarcinoma with immune infiltration  \nYanLi Chen1, Xinyao Xu1, Jipeng Zhang1, Chenghui Jia2, Liang-Guan3, Qirui Zhao3, Pengyu Jing1 & Qiang Lu1􀀍  \nLung cancer is a leading cause of cancer-related deaths, often resistant to conventional therapies like platinum-based chemotherapy. Identifying new biomarkers and therapeutic targets is essential for improving outcomes. In this study, we explored the role ofCDCA3 in lung adenocarcinoma (LUAD) as a prognostic marker and its association with immune cell infiltration and immunotherapy. Using data from The Cancer Genome Atlas (TCGA), we evaluated CDCA3 expression and its prognostic significance through Kaplan–Meier survival analysis. Our results showed that CDCA3 was significantly upregulated in LUAD tumor tissues compared to normal tissues, with higher CDCA3 expression linked to poorer overall survival. Additionally, CDCA3 expression correlated with clinical features such as age, gender, cancer stage, and smoking status. Immune infiltration analysis revealed significant associations with CD4-activated memory T cells and macrophages. Single-cell transcriptomics revealed that the proportions of CD8⁺ exhausted T cells, CD8⁺ cytotoxic T cells, M1 macrophages and M2 macrophages varied in association with CDCA3 expression levels in LUAD. CDCA3 expression also correlated with immune scores and immune checkpoint gene expression. Drug sensitivity analysis using the “oncoPredict” R package suggested that CDCA3 expression may influence chemotherapy responses. In vitro experiments inA549 cells showed that CDCA3 knockdown significantly reduced CDCA3 expression at both the mRNA and protein levels. While flow cytometry indicated increased apoptosis in CDCA3-knockdown cells, suggesting CDCA3’s role in promoting LUAD cell proliferation and survival. These findings indicated that CDCA3 could serve as a valuable prognostic biomarker in LUAD, influencing prognosis, immune response, and drug sensitivity, potentially guiding therapeutic and immunotherapy decisions.  \nKeywords CDCA3, Prognosis, Immune cell infiltration, Lung cancer, Lung adenocarcinoma  \nLung cancer ranks among the most prevalent malignancies, exhibiting the highest occurrence and morbidity rates1,with a poor 5 year survival rate of 19%2. It accounts for 29% of cancer-related deaths in males and 26% of cancer-related deaths in females3. Undoubtedly, smoking is the primary cause of lung cancer. In addition, it is worth noting that until recently, the incidence and mortality rates of lung cancer were higher in men than in women3. These facts demonstrate that lung cancer poses a significant threat to human health. According to pathological classification, lung cancer is categorized into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)4. Despite early surgical resection being the best cure for NSCLC, the majority of patients present with advanced or metastatic disease. Despite advances in targeted gene therapy, biomarkers, and immuno-oncology for advanced NSCLC, the 5-year survival rate for lung cancer patients is still below 20%, and even lower after metastasis5. Therefore, it is imperative to investigate the pathogenesis of lung cancer and identify therapeutic targets that possess high specificity and sensitivity.  \nIn our quest to discover new biomarkers or therapeutic targets, we have studied the protein Cell Division Cycle-Associated Protein 3 (CDCA3), also referred to as Tom-1, which is located on the human chromosome 12p13. CDCA3 is a component of the SKP1-Cullin-RING-F-box (SCF) ubiquitin ligase (E3) complex that targets the endogenous cell cycle inhibitor WEE1 G2 checkpoint kinase (WEE1) for degradation, thereby regulating the cell cycle6,7. Aberrations in the cell cycle have been linked to uncontrolled cell proliferation, which can  \n1Department of Thoracic Surgery, The Second Affilia","cbCaikx4yb6YJMRz","https://ap.wps.com/l/cbCaikx4yb6YJMRz","pdf",3979561,16,"English","# Introduction\n## Background: lung cancer burden and resistance\n## CDCA3 biology and rationale for LUAD study\n# Methods\n## Data source and expression/prognostic analysis\n## Immune infiltration and single-cell transcriptomics\n## Drug sensitivity and in vitro functional assays\n# Results\n## CDCA3 expression differences and survival association\n## Correlation with clinicopathological features\n## Links to immune infiltration, immune scores, and checkpoint genes\n## Chemotherapy response and CDCA3 knockdown effects","[{\"question\":\"What does CDCA3 expression indicate for patients with lung adenocarcinoma (LUAD)?\",\"answer\":\"CDCA3 is upregulated in LUAD tumor tissues, and higher expression is linked to poorer overall survival.\"},{\"question\":\"How is CDCA3 related to immune infiltration in LUAD?\",\"answer\":\"Immune infiltration analysis shows associations between CDCA3 levels and immune components including CD4-activated memory T cells and macrophages, with single-cell data indicating altered proportions of CD8⁺ exhausted and cytotoxic T cells and M1/M2 macrophages.\"},{\"question\":\"What experimental evidence supports CDCA3’s functional role in LUAD cells?\",\"answer\":\"In A549 cells, CDCA3 knockdown reduces CDCA3 mRNA and protein levels, and flow cytometry indicates increased apoptosis, consistent with CDCA3 promoting LUAD cell proliferation and survival.\"}]","Prognostic role of CDCA3 in lung adenocarcinoma with immune infiltration | PDF",1790124521,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92d96e3ca2eb89806959c922290d3808.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c2ab007ca830a019299756538d6094f.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a5d4939888e4b07e2a0db1124a51672.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f3c5bfb4bb4ead026477ff40e7c58fa.webp",980,1287]